In patients treated with anti-PD1 immunotherapy, ERBB3 mutation and a high TMB have been shown associated with prolonged survival, making them predictive biomarkers candidates in advanced cervical cancer (65, 66). Here, PDCD1 is linked to cervical carcinoma.